CGC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Canopy Growth Corp (CGC) is not an ideal buy for a beginner investor with a long-term focus at this time. While the company has shown some positive developments, such as revenue growth and international market expansion, the technical indicators, insider selling trends, and lack of strong proprietary trading signals suggest caution. Additionally, the stock's bearish technical setup and limited short-term upside make it unsuitable for immediate investment.
The technical indicators for CGC are bearish. The MACD histogram is negative and contracting, RSI is neutral at 33.072, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.95, with resistance at 1.011 and 1.073. This suggests limited upward momentum in the near term.
Canopy Growth achieved 10% revenue growth in fiscal
The acquisition of MTL Cannabis positions the company as a leader in Canada's medical cannabis market, with expected margin expansion in fiscal
International net revenue grew by 68% in Q4 2026, driven by regulatory relaxations in Germany.
The DEA's rescheduling announcement has boosted investor optimism about the cannabis sector.
Insiders are selling, with a 187.19% increase in selling activity over the last month.
Alliance Global lowered the price target to C$1.60 from C$1.80, citing fiscal Q4 sales and EBITDA below estimates.
The MACD and moving averages indicate a bearish trend, and the stock is trading near its support level.
No recent congress trading data or strong proprietary trading signals to support a buy decision.
Canopy Growth reported $71.2 million in net revenue for Q4 2026, with a widened adjusted EBITDA loss of $6 million due to inventory-related charges. However, the company reduced its free cash outflow to CA$69.1 million, showing financial discipline. The acquisition of MTL Cannabis is expected to yield $10 million in annual cost synergies, and the company is projected to achieve positive adjusted EBITDA by the end of fiscal 2027.
Analyst sentiment is mixed. Alliance Global maintains a Neutral rating with a lowered price target of C$1.60, citing underperformance in Q4 2026. Canaccord initiated coverage with a Buy rating and a C$2 price target, highlighting the company's pivot to an in-house supply model and its global competitive positioning.
